PainReform Ltd. (PRFX)
USD 2.1
(-2.33%)
USD 2.1
(-2.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.58 Million USD | 8.06% |
| 2022 | 8.86 Million USD | 23.04% |
| 2021 | 7.2 Million USD | 331.36% |
| 2020 | 1.67 Million USD | 142.53% |
| 2019 | 689 Thousand USD | 37.8% |
| 2018 | 500 Thousand USD | -42.99% |
| 2017 | 877 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.56 Million USD | 56.3% |
| 2024 Q2 | 7.34 Million USD | 32.08% |
| 2023 Q2 | 2.25 Million USD | -6.79% |
| 2023 Q1 | 2.41 Million USD | -25.8% |
| 2023 FY | 9.56 Million USD | 7.89% |
| 2023 Q4 | 3.55 Million USD | 163.17% |
| 2023 Q3 | 1.35 Million USD | -39.96% |
| 2022 Q3 | 2.09 Million USD | 13.6% |
| 2022 Q2 | 1.84 Million USD | 10.35% |
| 2022 Q1 | 1.67 Million USD | -3.96% |
| 2022 FY | 8.86 Million USD | 23.04% |
| 2022 Q4 | 3.25 Million USD | 55.34% |
| 2021 FY | 7.2 Million USD | 331.36% |
| 2021 Q2 | 1.66 Million USD | -18.59% |
| 2021 Q3 | 1.76 Million USD | 6.51% |
| 2021 Q4 | 1.74 Million USD | -1.53% |
| 2021 Q1 | 2.03 Million USD | 195.08% |
| 2020 FY | 1.67 Million USD | 142.53% |
| 2020 Q4 | 691 Thousand USD | -1.29% |
| 2020 Q1 | 132 Thousand USD | -41.2% |
| 2020 Q2 | 148 Thousand USD | 12.12% |
| 2020 Q3 | 700 Thousand USD | 372.97% |
| 2019 Q3 | 224.5 Thousand USD | 85.54% |
| 2019 FY | 689 Thousand USD | 37.8% |
| 2019 Q1 | 121 Thousand USD | 0.83% |
| 2019 Q2 | 121 Thousand USD | 0.0% |
| 2019 Q4 | 224.5 Thousand USD | 0.0% |
| 2018 Q1 | 132 Thousand USD | 0.0% |
| 2018 Q2 | 132 Thousand USD | 0.0% |
| 2018 Q3 | 120 Thousand USD | -9.09% |
| 2018 FY | 500 Thousand USD | -42.99% |
| 2018 Q4 | 120 Thousand USD | 0.0% |
| 2017 FY | 877 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -16.129% |
| Alpha Teknova, Inc. | 45.85 Million USD | 79.101% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 95.11% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 78.633% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 93.98% |
| Cosmos Health Inc. | 26.18 Million USD | 63.393% |
| Journey Medical Corporation | 54.59 Million USD | 82.445% |
| Embecta Corp. | 528.4 Million USD | 98.186% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 96.475% |
| Dynavax Technologies Corporation | 219.14 Million USD | 95.627% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 98.376% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 97.064% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 26.976% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 26.976% |
| SCYNEXIS, Inc. | 51.84 Million USD | 81.515% |
| Safety Shot Inc | 12.1 Million USD | 20.857% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -212.265% |
| Procaps Group, S.A. | 199.47 Million USD | 95.195% |
| Theratechnologies Inc. | 72.75 Million USD | 86.827% |
| Harrow Health, Inc. | 89.97 Million USD | 89.348% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -1.461% |
| Biofrontera Inc. | 39.95 Million USD | 76.015% |
| DURECT Corporation | 43.71 Million USD | 78.076% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 98.188% |
| Cronos Group Inc. | 96.7 Million USD | 90.09% |
| OptiNose, Inc. | 85.1 Million USD | 88.738% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 95.871% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 75.522% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 200.241% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 96.949% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | 1.509% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 77.733% |
| Radius Health, Inc. | 265.92 Million USD | 96.396% |
| Universe Pharmaceuticals INC | 13.84 Million USD | 30.761% |
| ProPhase Labs, Inc. | 37.85 Million USD | 74.68% |
| Phibro Animal Health Corporation | 260.29 Million USD | 96.318% |
| Procaps Group S.A. | 187.24 Million USD | 94.882% |
| Alvotech | 285.43 Million USD | 96.642% |
| TherapeuticsMD, Inc. | 9.82 Million USD | 2.453% |
| Viatris Inc. | 5.96 Billion USD | 99.839% |
| Rockwell Medical, Inc. | 15.37 Million USD | 37.661% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 83.984% |
| SIGA Technologies, Inc. | 22.04 Million USD | 56.521% |
| Tilray Brands, Inc. | 251.35 Million USD | 96.187% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 80.456% |
| Shineco, Inc. | 17.94 Million USD | 46.601% |
| PetIQ, Inc. | 192.72 Million USD | 95.027% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -140.132% |
| Incannex Healthcare Limited | 30.05 Million USD | 68.11% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.4% |
| Alimera Sciences, Inc. | 62.64 Million USD | 84.7% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -1156.931% |
| Assertio Holdings, Inc. | 368.58 Million USD | 97.4% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -62.839% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | 46.183% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 54.726% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 54.453% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 94.19% |
| Hempacco Co., Inc. | 7.59 Million USD | -26.164% |
| Talphera, Inc. | 11.99 Million USD | 20.093% |
| Alvotech | 285.43 Million USD | 96.642% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 93.189% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 97.221% |
| Currenc Group, Inc. | 24 Million USD | 60.07% |
| Kamada Ltd. | 45.42 Million USD | 78.902% |
| Indivior PLC | 911 Million USD | 98.948% |
| Evoke Pharma, Inc. | 12.4 Million USD | 22.77% |
| Flora Growth Corp. | 10.57 Million USD | 9.405% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 54.453% |
| Evolus, Inc. | 189.75 Million USD | 94.949% |
| HUTCHMED (China) Limited | 436.23 Million USD | 97.803% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 93.782% |
| Akanda Corp. | 3.48 Million USD | -175.125% |